- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Clinical smart watch finds success at identifying atrial fibrillation
Team of researchers led by Ghanbari has developed a prescription Verily Study wristwatch that continuously monitors the wearer's heart rhythm and uses a unique algorithm to accurately detect atrial fibrillation.The results are published in the Journal of the American Heart Association.
The use of wearable technology has grown tremendously and smart watches have been marketed across the globe to consumers as a way to monitor health.
For some, they’re told by these devices that they have atrial fibrillation, an irregular heartbeat, which is known to increase the risk of heart attack and stroke.
“Unfortunately, this has led to a tsunami of healthy patients coming to clinics complaining about having atrial fibrillation, and we see many false positives without really having a way to use these devices clinically,” said Hamid Ghanbari, M.D., M.P.H., a cardiac electrophysiologist the University of Michigan Health Frankel Cardiovascular Center.
“Right now, we typically manage patients with atrial fibrillation using electrocardiogram, or ECG, patches that we put on the chest, but the future of Afib management will be on the wrist,” said Ghanbari, lead author of the study and an assistant professor of internal medicine-cardiology at U-M Medical School.
Much like consumer wearable devices, the Verily Study Watch detects subtle changes in heart rhythm by sending light pulses through the skin into the blood vessels, a process known as photoplethysmography.
If it suspected atrial fibrillation, the device would prompt a user to take a single-lead ECG to determine if the algorithm correctly identified to Afib.
The results would then be reviewed by a cardiographic technician before it was reported to the participant’s physician.
The device analyzed data every 15 minutes, and its deep neural network algorithm determined whether over 100 participants had atrial fibrillation between September 2020 and May 2021.
The study watch correctly identified atrial fibrillation in the vast majority of participants, with levels of false negatives and positives that was similar to other devices for detection of Afib using similar photoplethysmography technology.
Although there was a decrease in performance of the device for some episodes of atrial fibrillation for participants with darker skin tones, it was still able to detect Afib in those patients.
Researchers say this is the first study to report the performance of the photoplenthysmography-based algorithm for participants at all levels of physical activity.
The device’s accuracy of detecting atrial fibrillation was comparable during low and moderate levels of activity.
Consumer-facing devices, like Apple Watch and Fitbit, are cleared by the United States Food and Drug Administration for pre-diagnostic purposes but are not intended for clinical decision making.
This device, Ghanbari says, could provide the link that allows providers to effectively use data from wearables to manage patients with Afib.
“The prescription Study Watch bridges the gap between long term, continuous monitoring that is currently more invasive and the consumer space with a practical solution for Afib detection and burden assessment,” he said.
“It is not intended to replace interval ECG monitoring for patients who need it. However, the multistage system may also limit the burden on clinicians and avoid the deluge of notifications generated by other wrist-worn devices that rarely result in clinically actionable findings.”
The creator of the watch, Verily Life Sciences, received 510(k) clearance from the FDA, a premarket submission to demonstrate the product’s efficacy and similarity to a legally marketed device.
“There is a need for clinical grade wrist-worn wearable that is affordable and can be prescribed by clinicians for the long term, personalized and continuous management of patients with Afib,” Ghanbari said.
Reference:
Ming‐Zher Poh, Anthony J. Battisti, Li‐Fang Cheng, Janice Lin, Anil Patwardhan, Ganesh S. Venkataraman, Charles A. Athill, Nimesh S. Patel, Chinmay P. Patel, Validation of a Deep Learning Algorithm for Continuous, Real‐Time Detection of Atrial Fibrillation Using a Wrist‐Worn Device in an Ambulatory Environment, https://doi.org/10.1161/JAHA.123.030543.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751